🏛️ Verified NIH Record • Updated 2026-05-12
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) (NCT06966479)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Upstream Bio Inc.
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (7 items).
Location: Kern Research, Inc. — Bakersfield, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Abnormal medical history, physical finding, or safety finding that in the opinion of the Investigator may obscure the study data or interfere with the participant's safety.
- Any clinical laboratory test result outside of the reference ranges considered by the Investigator as clinically significant and that may obscure the study data or interfere with the participant's safety.
- Participant with a history or evidence of a clinically significant pulmonary condition (other than asthma), including significant restrictive findings on pulmonary function testing, chronic bronchitis, emphysema, bronchiectasis, pulmonary fibrosis, or any other related condition that may obscure the study data (e.g., gastroesophageal reflux and vocal cord paralysis/dysfunction).
- Pregnant or breastfeeding or planning to become pregnant or breastfeed during the study or unwilling to use adequate birth control, if of reproductive potential and sexually active.
- Participants with significant protocol deviations in VALIANT, assessed at the discretion of the Sponsor.
- Participant is unreliable, incapable of adhering to the protocol and visit schedule according to the judgment of the Investigator or has any disorder that may compromise their ability to give informed consent.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (102 Sites)
- Kern Research, Inc. — Bakersfield, California
- California Medical Research Associates Inc. — Northridge, California
- Integrated Research of Inland Inc — Upland, California
- Allergy & Asthma Clinical Research — Walnut Creek, California
- Allianz Research Institute — Westminster, California
- Advance Pharma Research — Cutler Bay, Florida
- Clinical Site Partners, LLC dba Flourish Research — Miami, Florida
- Phoenix Medical Research — Miami, Florida
- Research Institute of South Florida — Miami, Florida
- Health and Life Research Institute, LLC — Miami, Florida
- Nouvelle Clinical Research — Miami, Florida
- Edward Jenner Research Group, LLC — Plantation, Florida
- R&B Medical Center — Tampa, Florida
- Clinical Site Partners dba Flourish research — Winter Park, Florida
- Treasure Valley Medical Research — Boise, Idaho
- Chesapeake Clinical Research Inc — White Marsh, Maryland
- Pulmonary Research Institute of Southeast Michigan (PRISM) — Farmington Hills, Michigan
- AA MRC — Flint, Michigan
- M3 Wake Research — Las Vegas, Nevada
- Urban Health Plan INC — The Bronx, New York
- Toledo Institute of Clinical Research Inc — Toledo, Ohio
- OK Clinical Research, LLC — Edmond, Oklahoma
- Horizon Clinical Research — Cypress, Texas
- Alina Clinical Trials, LLC — Dallas, Texas
- El Paso Pulmonary Association — El Paso, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.